GeneMedicine deal

The Houston company and Syntex Corp. (Palo Alto, Calif.) will develop gene medicines using non-viral delivery systems to treat rheumatoid arthritis, osteoarthritis and asthma, and to prevent organ transplant rejection.

GeneMedicine will provide a license to its technologies for gene-based drugs including controlled, cell-specific gene expression and non-viral delivery systems. Syntex will provide technologies in biochemistry and cell biology related to inflammatory and immunological diseases. ...